Get the Stockscreener App
0.543
1.27%
-0.007
After Hours:
.54
-0.003
-0.55%
Azitra Inc stock is traded at $0.543, with a volume of 144.68K.
It is down -1.27% in the last 24 hours and down -15.81% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.55
Open:
$0.5748
24h Volume:
144.68K
Relative Volume:
0.05
Market Cap:
$4.14M
Revenue:
$686.00K
Net Income/Loss:
$-11.76M
P/E Ratio:
-0.176
EPS:
-3.0856
Net Cash Flow:
$-9.40M
1W Performance:
+1.50%
1M Performance:
-15.81%
6M Performance:
+164.23%
1Y Performance:
-63.80%
1-Day Range:
$0.5201
$0.5748
1-Week Range:
$0.5201
$0.6101
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Azitra Inc Stock (AZTR) Latest News
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Canada
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - StockTitan
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World
Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World
Azitra Inc’s latest rating changes from various analysts - Knox Daily
A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News
Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex
Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News
Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance
Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com
Views of Wall Street’s Leading Experts on Azitra Inc - SETE News
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - StockTitan
Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex
Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily
FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com
Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - StockTitan
A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News
Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily
Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Understanding AZTR stock ratios for better investment decisions - US Post News
Ratio Revelations: Azitra Inc (AZTR)’s Financial Metrics in the Spotlight - The Dwinnex
Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Clinical Trials Arena
Azitra screens first subject in Phase Ib trial of ATR-12 for Netherton syndrome - Yahoo Finance
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra, Inc. Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of ATR-12 for Netherton Syndrome - Marketscreener.com
Azitra (NYSEAMERICAN:AZTR) Issues Earnings Results - Defense World
Stock Performance Spotlight: Azitra Inc (AZTR) Ends the Day at 0.70, Up by 2.94 - The Dwinnex
Azitra Inc’s Banking’s 100-Day Moving Average at 4.5289: Will the Stock Break Through? - The InvestChronicle
Get in on Azitra Inc’s (AZTR) buy-in window today! - SETE News
Checking in on Azitra Inc (AZTR) after recent insiders movement - Knox Daily
why Azitra Inc [AZTR] is a Good Choice for Investors After New Price Target of $3.50 - The DBT News
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates - Marketscreener.com
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates - wallstreet:online
Azitra : Announces Q2 2024 Financial Results and Provides Business Updates Form 8 K - Marketscreener.com
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates - StockTitan
Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Quantisnow
Azitra Inc (AZTR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
AZTR Stock Sees Decline of Approximately -32.11% in Last Five Days - Knox Daily
You might want to take a look at Azitra Inc (AZTR) now - SETE News
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Cap:
|
Volume (24h):